HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

492.989

-10.409-2.07%

Number of Gainers:7

Number of Losers:22

Number of Flat:4

PE:- -

High:505.901

Open:503.516

Low:489.571

Close:503.398

Volume:67.28M

Turnover:2.27B

Market Cap:314.91B

Float Cap:278.68B

Loading ...

Hong Kong Stock Market Flash: BRII-B Surges Over 8% as Interim Loss Narrows 32.08% and Promising Clinical Data Emerges

ZYLOXTB Surges Over 9% Intraday on Strong H1 Net Profit of 179 Million Yuan, Up 47.8% Year-On-Year

HUA MEDICINE-B (02552) Balances Stability with Progress: HuaTangNing® Commercial Expansion Paves the Way for Global Value Delivery

When This Sector Rallies, Tech Takes a Backseat

China's Brii Biosciences Interim Net Loss Narrows on Lower R&D Expenses

Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results

THOMSON REUTERS

Brii Biosciences: Hy Other Income Rmb19.5 Mln

THOMSON REUTERS

Brii Bio H1 FY26 Loss Narrows 32.1% to RMB 101 Million

Everest Medicines Limited (HKG:1952) Interim Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Simply Wall St.

CSTONE PHARMA-B Gets NMPA Green Light for CS5007 Investigational New Drug Application

SinoMab BioScience Announces Extraordinary General Meeting

CStone Says China NMPA Clears IND for Cs5007 Egfr/her3 Bispecific ADC

CStone Pharmaceuticals - Receives Nmpa Ind Approval for Cs5007 in China

THOMSON REUTERS

Keymed Biosciences (SEHK:2162) Stock Questions Whether New Profit Can Last

Simply Wall St.

Zylox-Tonbridge Delivers Strong First-Half 2026 Results as International Revenue Surges 349%

THOMSON REUTERS

Huapont Life Sciences Emphasizes R&D Commitment and AI Efficiency Initiatives

KeyMed Biosciences Announces 2026 H1 Results and Business Updates

THOMSON REUTERS

Press Release: Keymed Biosciences Announces 2026 H1 Results and Business Updates

ZYLOXTB Posts 31% Revenue Growth in 2026 Interim Results, Overseas Sales Surge 349%

Chinese Medical Device Maker Zylox-Tonbridge's Revenue Rises 31%, Aided by Global Expansion

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/BK1574/news?page=15"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":492.98874,"timestamp":1788246078966,"preClose":503.39795,"halted":0,"volume":67280135,"delay":0,"changeRate":-0.020678,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-10.40921,"latestTime":"09-01 15:01:20","open":503.51608,"high":505.9005,"low":489.5706,"amount":2265808233,"amplitude":0.032439,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788250200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1788226200000,1788235200000],[1788238800000,1788249600000]],"pbRate":3.790203,"peRate":127.340212,"turnoverRate":0.002561,"increases":7,"decrements":22,"flats":3,"marketCap":314911129296,"floatMarketCap":278679178584},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":505.9005,"amplitude":0.032439,"preClose":503.39795,"low":489.5706,"pbRate":"3.790203","latestPrice":492.98874,"volume":67280135,"delay":0,"open":503.51608,"prevYearClose":556.26263,"prevWeekClose":523.873,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":512.773,"twentyDayClose":475.248,"sixtyDayClose":459.637,"secType":"PLATE","market":"HK","turnoverRate":0.002561,"peRate":127.340212,"marketCap":314911129296,"floatMarketCap":278679178584,"timestamp":1788246078966,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":7,"down":22,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:15,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1179632017","title":"Hong Kong Stock Market Flash: BRII-B Surges Over 8% as Interim Loss Narrows 32.08% and Promising Clinical Data Emerges","url":"https://stock-news.laohu8.com/highlight/detail?id=1179632017","media":"Stock News","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179632017?lang=en_us&edition=fundamental","pubTime":"2026-08-21 11:41","pubTimestamp":1787283672,"startTime":"0","endTime":"0","summary":"Shares of BRII-B (02137) climbed more than 8% before the midday break, trading up 8.16% at HK$1.06 with turnover reaching HK$52.37 million.The company released its interim results for the six months...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK1574","KCAI","VXUS","BK1161","BK1587","02137","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108482719","title":"ZYLOXTB Surges Over 9% Intraday on Strong H1 Net Profit of 179 Million Yuan, Up 47.8% Year-On-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1108482719","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108482719?lang=en_us&edition=fundamental","pubTime":"2026-08-21 10:10","pubTimestamp":1787278248,"startTime":"0","endTime":"0","summary":"ZYLOXTB (02190) saw its shares climb more than 9% following the release of its interim results, before settling to a gain of 5.48% at 20.78 Hong Kong dollars, with turnover reaching 21.85 million...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1587","BK1100","BK1583","02190"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110843655","title":"HUA MEDICINE-B (02552) Balances Stability with Progress: HuaTangNing® Commercial Expansion Paves the Way for Global Value Delivery","url":"https://stock-news.laohu8.com/highlight/detail?id=1110843655","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110843655?lang=en_us&edition=fundamental","pubTime":"2026-08-21 09:28","pubTimestamp":1787275712,"startTime":"0","endTime":"0","summary":"The Hong Kong-listed innovative drug index (931787) has climbed over 10% since August, with a maximum rebound of more than 38% from its half-year low hit in early June. The current rally is primarily...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02552","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165297527","title":"When This Sector Rallies, Tech Takes a Backseat","url":"https://stock-news.laohu8.com/highlight/detail?id=1165297527","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165297527?lang=en_us&edition=fundamental","pubTime":"2026-08-21 09:10","pubTimestamp":1787274639,"startTime":"0","endTime":"0","summary":"On August 19th, the U.S. Treasury Department unexpectedly decided to at least double its long-term bond repurchase program, directly pushing global yields lower. While many assumed tech stocks would...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNGR","BK1574","BK1161","GLD","IBBQ","MEDX","518880","GCmain","SGUmain","SGCmain","06978","NUGT","159934"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661125866","title":"China's Brii Biosciences Interim Net Loss Narrows on Lower R&D Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2661125866","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661125866?lang=en_us&edition=fundamental","pubTime":"2026-08-21 07:14","pubTimestamp":1787267641,"startTime":"0","endTime":"0","summary":"China's Brii Biosciences interim net loss narrows on lower R&D expensesOverviewChina biotech firm's interim net loss narrowed for six months ended June 30, 2026Lower R&D and administrative expenses co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nL1N44H13O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1587","02137","BK1574","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661638258","title":"Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2661638258","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661638258?lang=en_us&edition=fundamental","pubTime":"2026-08-21 07:10","pubTimestamp":1787267400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nTUABLCVSX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1587","BK1574","02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661325830","title":"Brii Biosciences: Hy Other Income Rmb19.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2661325830","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661325830?lang=en_us&edition=fundamental","pubTime":"2026-08-21 07:02","pubTimestamp":1787266922,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nPLXMQ7KNH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1587","BK1574","02137","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661258376","title":"Brii Bio H1 FY26 Loss Narrows 32.1% to RMB 101 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661258376","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661258376?lang=en_us&edition=fundamental","pubTime":"2026-08-21 07:01","pubTimestamp":1787266863,"startTime":"0","endTime":"0","summary":"Brii Bio H1 FY26 loss narrows 32.1% to RMB 101 millionBrii Bio posted an IFRS net loss of RMB 101 million, narrowing 32.1% from a year earlier; basic loss per share improved to RMB 0.14.Other income f","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDL4prdW4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137","BK1161","BK1574","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661256976","title":"Everest Medicines Limited (HKG:1952) Interim Results Just Came Out: Here's What Analysts Are Forecasting For This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2661256976","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661256976?lang=en_us&edition=fundamental","pubTime":"2026-08-21 06:51","pubTimestamp":1787266310,"startTime":"0","endTime":"0","summary":"It's been a pretty great week for Everest Medicines Limited ( HKG:1952 ) shareholders, with its shares surging 18% to...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-limited-hkg1952-interim-results-just-came","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-limited-hkg1952-interim-results-just-came","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["VOTE","PMDE","RGLO","01952","DECU","MDCO","BK1574","BK1161","FEBU","GXDW","VGFPF","JOYT","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163462206","title":"CSTONE PHARMA-B Gets NMPA Green Light for CS5007 Investigational New Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1163462206","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163462206?lang=en_us&edition=fundamental","pubTime":"2026-08-21 06:12","pubTimestamp":1787263936,"startTime":"0","endTime":"0","summary":"CSTONE PHARMA-B (02616) has announced that the Investigational New Drug (IND) application for CS5007, an EGFR/HER3 bispecific antibody-drug conjugate (ADC) and one of the core candidates in the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","BK4080","NETL","BK1161","IND","BK1574","02616","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661230661","title":"SinoMab BioScience Announces Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2661230661","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661230661?lang=en_us&edition=fundamental","pubTime":"2026-08-21 06:07","pubTimestamp":1787263657,"startTime":"0","endTime":"0","summary":"SinoMab BioScience announces extraordinary general meetingSinoMab BioScience will hold an extraordinary general meeting in Central, Hong Kong on Sept. 7, 2026.Shareholders will vote on the proposed di","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDLbFrYsr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661923056","title":"CStone Says China NMPA Clears IND for Cs5007 Egfr/her3 Bispecific ADC","url":"https://stock-news.laohu8.com/highlight/detail?id=2661923056","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661923056?lang=en_us&edition=fundamental","pubTime":"2026-08-21 06:02","pubTimestamp":1787263372,"startTime":"0","endTime":"0","summary":"CStone says China NMPA clears IND for CS5007 EGFR/HER3 bispecific ADCCStone Pharmaceuticals secured China NMPA clearance for an IND to start clinical trials of CS5007, an EGFR/HER3 bispecific ADC.The ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDL2K2DjY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661305552","title":"CStone Pharmaceuticals - Receives Nmpa Ind Approval for Cs5007 in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2661305552","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661305552?lang=en_us&edition=fundamental","pubTime":"2026-08-21 06:02","pubTimestamp":1787263355,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nFWN44H1HS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1161","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661303292","title":"Keymed Biosciences (SEHK:2162) Stock Questions Whether New Profit Can Last","url":"https://stock-news.laohu8.com/highlight/detail?id=2661303292","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661303292?lang=en_us&edition=fundamental","pubTime":"2026-08-21 04:33","pubTimestamp":1787257986,"startTime":"0","endTime":"0","summary":"Keymed Biosciences stock has cooled in recent weeks, with the share price down about 10.6% over the past month even after moving into the black over the last year. Today's earnings story is all about profit, not hype. Basic earnings per share for the first half of 2026 came in at ¥4.29, flipping from losses in 2025, and trailing twelve month earnings now support a P/E of 25.4x.\nThe market is treating that P/E as a question mark. The key issue now is whether investors see this new...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/keymed-biosciences-sehk2162-stock-questions-whether-new-prof","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/keymed-biosciences-sehk2162-stock-questions-whether-new-prof","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1587","VGFPF","BK1574","DECU","02162","FEBU","GXDW","RGLO","BK1583","PMDE","BK1161","JOYT","VOTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660233120","title":"Zylox-Tonbridge Delivers Strong First-Half 2026 Results as International Revenue Surges 349%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660233120","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660233120?lang=en_us&edition=fundamental","pubTime":"2026-08-20 23:10","pubTimestamp":1787238639,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nTUACZXYM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1587","02190","BK1100","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183357927","title":"Huapont Life Sciences Emphasizes R&D Commitment and AI Efficiency Initiatives","url":"https://stock-news.laohu8.com/highlight/detail?id=1183357927","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183357927?lang=en_us&edition=fundamental","pubTime":"2026-08-20 22:32","pubTimestamp":1787236368,"startTime":"0","endTime":"0","summary":"On August 20, Huapont Life Sciences Co.,Ltd. addressed investor inquiries on its interactive platform, stating that the company adheres to a strategy of combining innovative and generic drug...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0146","BK1574","BK0114","BK1161","159938","BK1515","09939","BK0174","BK0042","002004","BK0229","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660427280","title":"KeyMed Biosciences Announces 2026 H1 Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2660427280","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660427280?lang=en_us&edition=fundamental","pubTime":"2026-08-20 22:10","pubTimestamp":1787235014,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nTUA5MDWKS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1587","BK1161","02162","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660232280","title":"Press Release: Keymed Biosciences Announces 2026 H1 Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2660232280","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660232280?lang=en_us&edition=fundamental","pubTime":"2026-08-20 22:10","pubTimestamp":1787235000,"startTime":"0","endTime":"0","summary":"CHENGDU, China, Aug. 20, 2026 /PRNewswire/ -- On August 19, 2026, Keymed Biosciences (HKEX: 02162) announced its interim results for the six months ended June 30, 2026. Guided by a clear dual-engine d","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4096","BK1574","BK1587","PN","BK1583","BK1161","02162","BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114693671","title":"ZYLOXTB Posts 31% Revenue Growth in 2026 Interim Results, Overseas Sales Surge 349%","url":"https://stock-news.laohu8.com/highlight/detail?id=1114693671","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114693671?lang=en_us&edition=fundamental","pubTime":"2026-08-20 21:51","pubTimestamp":1787233900,"startTime":"0","endTime":"0","summary":"ZYLOXTB (HKEX: 02190) unveiled its interim results for the first half of 2026 on August 20, showcasing robust financial performance. The company recorded operating revenue of RMB 632 million for the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","BK1574","02190","BK1583","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660287767","title":"Chinese Medical Device Maker Zylox-Tonbridge's Revenue Rises 31%, Aided by Global Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2660287767","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660287767?lang=en_us&edition=fundamental","pubTime":"2026-08-20 21:40","pubTimestamp":1787233202,"startTime":"0","endTime":"0","summary":"Chinese medical device maker Zylox-Tonbridge's revenue rises 31%, aided by global expansionOverviewChina medical device maker's H1 revenue rose 31.1% yr/yr, driven by device sales growthNet profit for","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nL1N44H0K9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02190","HK0000165453.HKD","BK1191","SG9999015945.SGD","00656","SG9999015986.USD","BK1230","IE00BVYPNQ40.USD","01696","BK1589","BK1593","IE00BZ08YR35.GBP","BK1583","IE00BGHQDM52.EUR","IE00BMCWC346.EUR","BK1587","BK1521","BK1585","SG9999015978.USD","BK1515","IE00BZ08YT58.USD","01177","00867","IE00BVYPNP33.GBP","BK1100","IE00BYV24P56.USD","IE00BZ08YS42.EUR","SG9999004220.SGD","BK1574","SG9999015952.SGD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":20,"pageCount":15,"totalSize":381,"code":"91000000","status":"200"}]}}